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The effects of (2-deoxy-2-fluoro-j8-D-arabinofuranosyl)-5-iodocytosine (FIAC), 1-(2-deoxy-2-fluoro-p-D-
arabinofuranosyl)-5-methyluridine (FMAU), 1-(2-deoxy-2-fluoro-,1-D-arabinofuranosyl)-5-iodouridine (FIAU),
(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU), and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG or BW
B759U) on the replication of Epstein-Barr virus (EBV) in vitro were evaluated and compared with that of
acyclovir (ACV). The relative potencies of these drugs, on the basis of anti-EBV activity, were: FIAC = FIAU
> FMAU > DHPG > BVdU > ACV; on the basis of the therapeutic index they were: BVdU > DHPG > FIAC
> ACV > FIAU > FMAU. Differential inhibition of EBV-associated polypeptides by these drugs was observed.





(DHPG or BW B759U), are potent inhibitors of Epstein-Barr
virus (EBV) replication in vitro (14, 16). These four drugs
have prolonged effects in suppressing viral replication, even
after the drugs are removed from persistently infected cell
cultures (14, 16). In the present studies we have extended
our previous findings and further characterized the efficacy
of each drug in parallel with acyclovir (ACV) in terms of
inhibition of replication of EBV in human lymphoblastoid
cell lines.
Exponentially growing P3HR-1 cells were fed (at 3-day
intervals) with fresh medium containing different concentra-
tions of drugs (0, 0.01, 0.1, 1, 10, and 100 ,uM) and incubated
for 14 days (16). At the end of drug treatment, cells were
harvested, and the number of EBV genome copies per cell
was determined by cRNA-DNA hybridization with an EBV-
specific cRNA probe as detailed elsewhere (13, 15).
A dose-dependent inhibitory effect was observed for each
drug tested. The number ofEBV genome copies per cell was
plotted against drug concentrations on a semilogarithmic
scale. Taking as the zero point the residual level of 30
genome copies per cell (16), from the plots we determined
the viral 50 and 90% effective doses (ED50 and ED90) of each
drug. The same graphical method was used to determine the
cell growth 50% inhibitory doses (ID50). The ID50s for
BVdU, FIAC, 1-(2-deoxy-2-fluoro-,-D-arabinofuranosyl)-5-
iodouridine (FIAU), and FMAU were, respectively, 390, 5,
1, and 1 ,uM. On the basis of these data, we calculated the
therapeutic index (ID5W/ED5o) for each drug (Table 1). For
comparative purposes, data on ACV and DHPG which were
published previously (16) are included.
The relative potencies of these drugs on the basis of
anti-EBV activities were: FIAC = FIAU > FMAU >
DHPG > BVdU > ACV; on the basis of the therapeutic
index they were: BVdU > DHPG > FIAC > ACV > FIAU
> FMAU (Table 1).
We compared the effects of BVdU, FIAC, FMAU, ACV,
and DHPG on the synthesis of EBV-associated polypeptides
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by polyacrylamide gel electrophoresis (12). Figure 1 shows
the results of a fluorogram (1) made by exposing an elec-
tropherogram of 35S-labeled polypeptides synthesized in
superinfected Raji cells in the presence and absence of
drugs. Superinfection of Raji cells (lane S), compared with
mock-infected cells (lane M), resulted in the synthesis of at
least seven new polypeptides with molecular weights of
145,000, 140,000, 135,000, 110,000, 85,000, 55,000, and
32,000, which were detected 24 h postinfection in a contin-
uous labeling experiment. The polypeptides with molecular
weights of 140,000 and 145,000 were partially inhibited by
ACV, FIAC, and FIAU, in contrast to being markedly
reduced by BVdU, FMAU, and DHPG. Differential inhibi-
tion of the 110,000-molecular-weight polypeptide by these
drugs was observed. In addition, synthesis of the 85,000-mo-
lecular-weight polypeptide was markedly reduced by DHPG
and FIAU, but it was not significantly reduced by FMAU,
FIAC, BVdU, or ACV.
The studies presented here clearly demonstrate that
DHPG, BVdU, FIAC, FMAU, and FIAU are potent inhib-
itors of EBV replication in culture. As with ACV, these
drugs effectively inhibit linear forms of EBV DNA, which
are replicated by virus-specific DNA polymerase, but have
no effect on the EBV plasmids, which are presumed to be
replicated by host enzyme.
Studies with ACV and BVdU have clearly indicated that
preferential phosphorylation of these compounds by the
virus-specific thymidine kinase is a prerequisite for their
selective activities against herpes simplex virus type 1(7, 11)
and herpes zoster virus (3). Although there is some evidence
TABLE 1. Inhibitory action of nucleoside analogs
Drug(E>Do ID50 TherapeuticDrug E5 index (IDS)V/(p.M) (pM) ~~~ED%))
ACV" 0.3 250 833
DHPGa 0.05 200 4,000
BVdU 0.06 390 6,500
FIAC 0.005 5 1,000
FIAU 0.005 1 200
FMAU 0.0065 1 154
a Data previously published (16).
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that of ACV (Lin et al., in press). The larger quantity of
DHPG triphosphate than of ACV triphosphate formed in
superinfected Raji cells may facilitate the incorporation of
DHPG into the internucleotide chain of EBV DNA, as
reported in herpes simplex virus-infected cells (4). Whether
the prolonged anti-EBV activities of DHPG, FIAC, FMAU,
and BVdU previously observed (14, 16) are related to the
accumulation of a stable pool of drug triphosphates remains
to be determined. It also remains to be established whether
the inhibition of EBV replication by these drugs follows a
mechanism similar to that reported in herpes simplex virus
(8).
The differential effects of the drugs on EBV-associated
polypeptides are consistent with their antiviral activities.
These findings are similar to our previous work on differen-
tial effects of DNA inhibitors on viral polypeptide synthesis
(9, 16). As is the case for most antiviral drugs, the effects of
these compounds on viral polypeptides are most likely due
to inhibition of EBV DNA synthesis. The differential reduc-
tion in EBV-induced polypeptide synthesis, although a sec-
ondary effect of the drugs, could play a role in the inhibition
of virus replication, as suggested in herpes simplex virus
systems (10, 19).
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FIG. 1. Differential effects of nucleoside analogs on synthesis of
EBV-associated polypeptides. Lanes M and S were polypeptides
synthesized in mock-infected and superinfected Raji cells, respec-
tively. Lanes A through F were polypeptides synthesized in super-
infected Raji cells in the presence of the drug specified at the top of
each lane. Concentrations of the drugs used were 10 times their
ED90s, i.e., 40 F.M BVdU, 100 ,uM ACV, 30 ,uM DHPG, and 1 ,uM
FIAC, FMAU, and FIAU. M.W., Molecular weight.
for and against the existence of an EBV-specific thymidine
kinase (2, 5, 6, 17, 18), there has been no unequivocal
demonstration of a novel enzyme activity induced by EBV
that might represent a virus-encoded thymidine kinase.
However, we have found that both DHPG and ACV were
preferentially phosphorylated in superinfected Raji cells, in
contrast to the low level of phosphorylation in mock-in-
fected Raji cells (J.-C. Lin, D. J. Nelson, C. U. Lambe,
E. I. Choi, and J. S. Pagano, in H. E. Kaufman and K.
Reisaku, ed., Pharmacological and Clinical Approaches to
Herpesvirus and Virus Chemotherapy, in press). EBV infec-
tion produced a rapid and marked increase inDHPG phospho-
rylating activity, and this activity was 100-fold higher than
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